GLP-1 agonists are emerging as a key development in chronic condition management, but they come with questions about clinical value, cost management, and evolving guidelines. Employers face the challenge of balancing these new therapies with practical benefits strategies. Meanwhile, pharmacy benefit managers (PBMs) may not always approach these trends as expected.
Marsh McLennan Agency recently hosted a webinar to help employers understand the latest trends in GLP-1 usage and clinical reviews, as well as the evolving role of PBMs and management strategies for GLP-1s. BenefitsPRO covered the conversation and the team’s recommendations for optimizing your pharmacy benefits offerings.
“Coverage of GLP-1s is not necessarily in-your-face obvious. It leads to the conversation of whether we want to pursue weight loss through drug products or something like a wellness program,” said Zak Kornblum, pharmacy clinical director at MMA.
Learn more via BenefitsPRO.
